Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25220765 | 0.86 | ALDH1A1 (0.41) | CYP1A2CYP2C19KMT2A | |
| Hydrochloric Acid SCHEMBL25409136 | 0.84 | ALDH1A1 (0.40) | CYP1A2CYP2C19KMT2A | |
| SCHEMBL25314965 | 0.76 | ALDH1A1 (0.31) | — | |
| SCHEMBL9912736 | 0.74 | GRIN1 (0.42) | CYP1A2CYP2C19KMT2A | |
| SCHEMBL19344901 | 0.70 | ADRA2A (0.30) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL25922819 | 0.69 | ALDH1A1 (0.34) | CYP1A2CYP2C19KMT2A | |
| SCHEMBL24147129 | 0.69 | — | — | |
| SCHEMBL31292327 | 0.68 | KDM4E (0.34) | — | |
| SCHEMBL15888817 | 0.67 | HDAC8 (0.30) | — | |
| SCHEMBL13069797 | 0.65 | CYP19A1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | AMGEN INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | IAPP, INSR, AMY2A | CYP1A2 83/4885CYP2C19 713/4885KMT2A 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.